Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL– Tumors
J Immunol Larmonier et al.
181: 6955
Data Supplement
Files in this Data Supplement:
Supplemental Figure S1 (PDF, 136 Kb) -
Effects of imatinib in combination with DC chemoimmunotherapy on A20 liver metastases. A20 tumor-bearing mice were treated as described in Fig. 7. The figure depicts each individual liver from the control, imatinib-treated, DC-treated, or imatinib plus DC- treated group of mice.